RNAi Technology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global RNAi Technology Market is projected to expand from USD 1.61 Billion in 2025 to USD 2.99 Billion by 2031, achieving a compound annual growth rate of 10.87%. This sector encompasses both research tools and therapeutics that employ RNA interference mechanisms to neutralize specific mRNA molecules, thereby inhibiting gene expression to address genetic disorders, viral infections, and malignancies. The market's growth is primarily driven by the increasing incidence of chronic diseases and the surging demand for precision medicine capable of treating targets that were previously considered undruggable. Furthermore, continuous advancements in drug delivery systems, particularly lipid nanoparticle formulations, are improving the stability and bioavailability of these therapeutics, which facilitates their broader clinical adoption.

Despite these advances, the complexity of delivering RNA molecules to tissues outside the liver presents a significant obstacle that limits the current therapeutic reach of these technologies. Developing solutions that ensure stability within the bloodstream and facilitate cellular uptake without provoking off-target immune reactions continues to complicate development timelines. However, the industry remains committed to overcoming these translational hurdles, as evidenced by data from the American Society of Gene & Cell Therapy; in the second quarter of 2025, the RNA therapy pipeline grew significantly with the initiation of 38 new clinical trials, signaling persistent investment in addressing these challenges.

Market Drivers

The escalating prevalence of cancer and chronic infectious diseases acts as a primary engine for growth in the Global RNAi Technology Market. Because conventional therapeutic modalities frequently struggle to address complex genetic drivers, RNA interference offers a unique mechanism for silencing specific disease-causing genes with high precision. This critical need is highlighted by the rising disease burden; the American Cancer Society's "Cancer Facts & Figures 2025" report projected that more than 2 million new cancer cases would be diagnosed in the United States in 2025. Consequently, the ability of RNAi therapeutics to engage targets previously deemed undruggable positions them as essential components of future treatment regimens for oncology and infectious diseases.

Simultaneously, strategic collaborations and licensing agreements within the life sciences sector are accelerating market expansion by providing the necessary capital to advance clinical pipelines. Leading pharmaceutical companies are increasingly partnering with specialized biotech firms to utilize proprietary platforms and mitigate development risks.

For example, GeneOnline reported in September 2025 that Novartis committed an additional $5.2 billion to its collaboration with Argo Biopharma to develop RNAi therapies for cardiovascular conditions. These alliances are effectively translating research and development into commercial reality; underscoring this progress, Arrowhead Pharmaceuticals announced in 2025 that the U.S. FDA approved plozasiran, a novel RNAi therapeutic for familial chylomicronemia syndrome.

Market Challenges

The difficulty of efficiently delivering RNA molecules to tissues beyond the liver constitutes a formidable barrier that hampers the expansion of the Global RNAi Technology Market. Although current technologies have proven successful for hepatic targets, the market is severely constrained by the challenge of engineering delivery vehicles capable of navigating to organs such as the brain, heart, or lungs without degrading or causing toxicity. This technical limitation confines the commercial scope of RNAi therapeutics to a narrow range of indications, effectively capping the addressable market and preventing entry into high-demand therapeutic areas like neurology and broad-spectrum oncology.

Consequently, the complexity of ensuring bloodstream stability and preventing off-target immune responses has introduced significant friction into the drug development process. These translational obstacles increase the risk profile of new candidates, leading to extended development timelines and a more cautious approach to clinical progression. The impact of these barriers is evident in recent industry metrics; according to the American Society of Gene & Cell Therapy, clinical development activity slowed across the broader gene, cell, and RNA landscape in the third quarter of 2025, with total trial initiations falling to 125 after a surge in the previous quarter. This contraction highlights how delivery-related difficulties directly throttle the pipeline's velocity and delay market maturation.

Market Trends

The commercialization of RNAi-based biopesticides and agricultural solutions is fundamentally diversifying the market beyond human therapeutics by addressing critical challenges in crop protection. This trend utilizes the specificity of RNA interference to silence essential genes in pests without harming beneficial insects or the environment, offering a sustainable alternative to conventional chemical agents. Industry players are increasingly securing capital to advance these eco-friendly platforms from the laboratory to field trials; for instance, Renaissance BioScience announced in September 2025 that it secured CAN$830,000 in funding from the Government of Canada to accelerate the development of its proprietary RNAi biocontrol technology for the agriculture sector.

Concurrently, an increasing reliance on Contract Development and Manufacturing Organizations (CDMOs) for scalable oligonucleotide manufacturing is emerging as a structural shift to support the mass production of RNAi therapeutics. As the pipeline expands into high-prevalence indications, developers are externalizing production to specialized organizations that offer the advanced capacity and regulatory expertise required for commercial volumes. This strategic outsourcing allows pharmaceutical firms to mitigate technical manufacturing risks and accelerate supply chain readiness for large-scale patient populations. Underscoring this expansion, Bachem reported in July 2025 that it invested CHF 129.1 million in the first half of the year specifically to expand production capacity across its global site network.

Key Players Profiled in the RNAi Technology Market

• Alnylam Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Atalanta Therapeutics Inc.
• Phio Pharmaceuticals Corp.
• Benitec Biopharma Ltd.
• Novartis AG
• AstraZeneca PLC
• Silence Therapeutics plc
• Arbutus Biopharma Corp.
• Sylentis S.A.

Report Scope

In this report, the Global RNAi Technology Market has been segmented into the following categories:

RNAi Technology Market, by Type:

• Micro RNA
• Small interfering RNA
• Others

RNAi Technology Market, by Application:

• Treatment Type
• Therapeutics
• Drug Delivery
• Agriculture
• Others

RNAi Technology Market, by End User:

• Research and Academic Laboratories
• Diagnostic Laboratories
• Others

RNAi Technology Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNAi Technology Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.